Clinical trials: Essential Hypertension.
Hypertension
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure
This is a study for people diagnosed with hypertension to compare 3 doses (75 mg, 150 mg, and 300 mg) of an experimental product, aliskiren in comparison to a placebo. Each patient is in the study for 8 weeks
- Trial name
- NCT00260923
- Testing
- aliskiren
- Where
- 2 sites in United States, Germany
- Volunteers
- 641 people
- Sponsor
- Novartis
Blood Pressure, Depression
Essential Hypotension and Allostasis Registry
The essential arterial hypotension and allostasis registry is a prospective, observational research that has the purpose of demonstrating that essential blood pressure (BP) disorders and the associated comorbidities are a result…
- Conditions
- Blood Pressure, Depression, Panic Attack, Fibromyalgia
- Trial name
- ESSENTIAL (NCT02018497)
- Where
- Colombia
- Volunteers
- 5,000 people
- Sponsor
- CES University
Essential Hypertension, Dyslipidemia
Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia
The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/amlodipine/rosuvastatin treatment group to the fimasartan/amlodipine treatment group and the fimasartan/rosuvastatin…
- Trial name
- FIRST (NCT03156842)
- Testing
- Fimasartan/Amlodipine, Rosuvastatin, Fimasartan/Amlodipine, Fimasartan, Rosuvastatin
- Where
- South Korea
- Volunteers
- 138 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb
This is a multi-center, randomized, placebo-controlled, time-lagged, parallel-group study in healthy and hypertensive subjects to evaluate safety and tolerability of the vaccine CYT006-AngQb.
- Trial name
- NCT00500786
- Testing
- CYT006-AngQb
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Cytos Biotechnology AG
Hypertension, Essential
Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions
Randomized, open label, single dose, 4-way crossover study to investigate the bioequivalence of a new fixed dose combination tablet of nifedipine GITS and candesartan with the corresponding loose combination and to compare it…
- Trial name
- NCT01227603
- Testing
- Nifedipine-candesartan FDC (BAY 98-7106), Nifedipine GITS (Adalat LA, BAYA1040), Candesartan (Atacand)
- Where
- Germany
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bayer
Essential Hypertension
Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.
The purpose of this study is to investigate the efficacy (blood pressure lowering effect) and safety of aliskiren given to hypertensive patients after a missed dose.
- Trial name
- NCT00343551
- Testing
- Aliskiren
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 654 people
- Sponsor
- Novartis
Hypertension, Hypertension, Systolic
Treatment of Hypertension During Sleep
On the basis of new evidence on the relationship between achieved office blood pressure (BP) measurements (OBPM) and the risk of cardiovascular disease (CVD) morbidity and mortality documented in the SPRINT trial, the recent 2017…
- Trial name
- THADEUS (NCT03457168)
- Testing
- Treatment of elevated asleep SBP mean
- Where
- 9 sites in Spain
- Volunteers
- 5,320 people
- Sponsor
- University of Vigo
Essential Hypertension
QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension
The purpose of the study is to evaluate the efficacy and safety of QR12000 75mg, QR12000 150mg and Sacubitril/valsartan 200mg in patients with moderate to severe essential hypertension.
- Trial name
- NCT06716970
- Testing
- QR12000 75mg, QR12000 150mg, Sacubitril/valsartan 200mg
- Where
- China
- Volunteers
- 810 people
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
Hypertension, Systolic, Stiffness, Aortic
Sympathetic Regulation of Large Artery Stiffness in Humans With ISH
Stiffening of your blood vessels, particularly the large vessels from your heart (called the aorta and carotids) you age contributes to the development of cardiovascular disease (CVD) such as heart attack and stroke.
- Trial name
- SELECT (NCT04423627)
- Testing
- Clonidine, Hydrochlorothiazide
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Iowa
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in Healthy Volunteers Fed Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015 and co-administration of BR1015-1 and BR1015-2 in healthy volunteers under fed conditions
- Trial name
- NCT06744062
- Testing
- BR1015, BR1015-1, BR1015-2
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension, Stage II Hypertension
Mat Pilates With Paced Breathing Versus Diaphragmatic Breathing in Stage II Hypertension
This randomized controlled trial aims to compare the effects of mat Pilates combined with paced breathing versus mat Pilates combined with diaphragmatic breathing on stress, anxiety, cardiopulmonary endurance, dyspnea, and…
- Conditions
- Hypertension, Stage II Hypertension, Essential Hypertension
- Trial name
- NCT07433790
- Testing
- Mat Pilates, Paced Breathing
- Where
- Pakistan
- Volunteers
- 63 people
- Sponsor
- University of Lahore
Hypertension
Study to Confirm the Efficacy and Safety of Fixed-dose Combinations of Amlodipine and Candesartan
To evaluate the efficacy and safety of amlodipine besylate and candesartan cilexetil administered in a fixed-dose combination tablet versus co-administered as their separate formulations in patients with essential hypertension…
- Trial name
- MACH (NCT03231982)
- Testing
- Group I, Group II
- Where
- South Korea
- Volunteers
- 210 people
- Sponsor
- HK inno.N Corporation
Hypertension
Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension
This study will compare the efficacy and safety of once daily dosing of aliskiren monotherapy to once daily dosing of aliskiren and hydrochlorothiazide combination therapy in patients with Stage II hypertension over a period of…
- Trial name
- ACQUIRE (NCT00705575)
- Testing
- Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg), Aliskiren (300 mg)
- Where
- 8 sites in United States, Argentina and 6 more
- Volunteers
- 688 people
- Sponsor
- Novartis
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-1 and BR1015-2 in healthy volunteers under fasting conditions
- Trial name
- NCT07421375
- Testing
- BR1015-A, BR1015-1, BR1015-2
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
To Evaluate Safety and Efficacy of a Radiofrequency Renal Denervation System in Treatment of Essential Hypertension
This is a prospective, multicenter, randomized sham-controlled trial to evaluate safety and efficacy of a multi-electrode radiofrequency renal denervation system (Netrod® System) in treating patients with uncontrolled essential…
- Trial name
- NCT03261375
- Testing
- Renal Artery Radiofrequency Ablation System (Generator and Catheter ), Antihypertensive Agents
- Where
- 25 sites in China
- Volunteers
- 205 people
- Sponsor
- Shanghai Golden Leaf MedTec Co. Ltd
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015 and co-administration of BR1015-1 and BR1015-2 in healthy volunteers under fasting conditions
- Trial name
- NCT06744127
- Testing
- BR1015, BR1015-1, BR1015-2
- Where
- South Korea
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan/Hydrochlorothiazide combination 60/12.5mg~120/12.5mg in patients with essential hypertension who are not controlled by fimasartan…
- Trial name
- NCT01258673
- Testing
- Fimasartan/HCTZ combination, Fimasartan
- Where
- South Korea
- Volunteers
- 263 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
The Effect of a Homoeopathic Complex on Blood Pressure in Refractory Hypertension
Refractory hypertension is defined as failure to reach goal blood pressure control in patients who are adherent to full doses of the appropriate drug regime.
- Trial name
- NCT02419235
- Testing
- 20% ethanol, Homoeopathic complex
- Where
- South Africa
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Johannesburg
Essential Hypertension
To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil
The main objective of the study will be to assess the efficacy and safety of Allisartan Isoproxil/sustained-release indapamide (240 mg/1.5 mg) in patients with mild to moderate essential hypertension uncontrolled after 4-week…
- Trial name
- NCT06500689
- Testing
- Allisartan Isoproxil/Sustained-Release Indapamide, Allisartan Isoproxil
- Where
- 40 sites in China
- Volunteers
- 366 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Primary Hypertension
Effect of Aerobic EXercise on MiCroVAscular RarefacTION in Chinese Mild HyperteNsive Patients（EXCAVATION-CHN1）
The purpose of this study is to determine the effect of aerobic exercise training on microcirculation rarefaction in Chinese young male primary hypertensive patients stage 1.
- Trial name
- NCT02817204
- Testing
- Aerobic Exercise, Health Education
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University